Somewhere in your search history there is now a phrase like GLP-1 without injections, typed after a conversation that did not go the way you hoped. Someone you love has a lab result that came back flagged, or a weight they have fought for years. When you mentioned the medication that seems to be everywhere, the answer was short: "I'm not injecting anything." You are not trying to talk them out of that. You want to understand what a membership would actually ask of them before you raise it again, so that the next conversation starts from facts instead of an advertisement.
This piece follows one person through her first three months as a GoodLife Health patient, from the eligibility check to her second set of labs. We will call her Dana. Dana is a composite, assembled to show how the process works; she is not a real patient, and nothing in her story is a promise about anyone else's. At each step we say what is checked and why, what it costs, and where a needle does and does not come into it.
- A GoodLife Health membership starts with labs and a clinician's review, before any prescription.
- Oral GLP-1 options exist, including the Wegovy pill from $149 a month at lower doses (NovoCare, September 2026).
- Whether any medication is indicated, and in what form, is the clinician's decision; neither a pill nor an injection is promised.
- Four lab panels a year mean four blood draws, so "no needles at all" is not on offer.
- The fee is $299 a month whatever is prescribed; medication is billed separately by the patient's chosen pharmacy.
The conversation you are preparing for
Dana is in her early fifties. At her last annual physical, one line of her bloodwork was marked elevated, and the visit ended with a suggestion to keep an eye on it and come back next year. She has tried the diets, more than once. She has also seen the advertisements, and nearly every one opens on the same image: a pen, a cap coming off, a calm voice explaining how small the needle is. For Dana, that image ends the conversation. Part of it is a plain dislike of needles. Part of it is that a regular injection feels like crossing a line into being someone with a condition, and she is not ready to see herself that way.
You can see both sides of it. You have watched her work at this for a long time, and you have heard enough about these medications to wonder whether one of them could help. What you do not want is to push her toward something she has already refused. You also do not want to sign up for a program that turns out to be a box of pens on the doorstep and a charge on the card every month.
That worry is reasonable, because much of this market is organized around exactly that box. Many services compete on access to a particular molecule and the price of delivering it, and the advertising you have seen shows a pen. If that is the only model you have met, it is natural to assume that every medical weight program begins with the question "which pen?" From there it seems to follow that refusing the pen means refusing the whole thing.
So the questions you are carrying are practical. What would Dana be agreeing to? Would anyone try to talk her into injecting? What happens if the answer on medication is no, or not yet? What does it cost, and what does the money not buy? The rest of this piece answers them in the order she would meet them.
What is actually going on: the needle is a late question, if it comes up at all
GoodLife Health is built the other way around. The model is labs-first: diagnosis first, then treatment, then the long haul. Before anyone discusses a prescription, a clinician wants to know what is happening in Dana's body, and weight is only one part of that. Our cost comparison guide lists what services built around the scale are not designed to look for: the thyroid quietly stalling progress, the fasting insulin rising years before glucose moves, the ApoB that stays dangerous after the scale improves, and the hormonal transition driving the weight in the first place. Any one of those findings can change what treatment makes sense.
When medication is indicated, there are more forms to choose from than the advertising suggests. GLP-1 medication comes in injected forms, such as Wegovy pens and Zepbound vials, and in oral forms taken by mouth, such as the Wegovy pill and Foundayo (orforglipron). GLP-1 without injections is a real category of treatment, then, and more than a marketing phrase. Whether an oral option suits a particular patient is a clinical judgment, made by a clinician who has read that patient's labs and history. The membership does not promise a pill, any more than it promises an injection.
What the pricing does settle is that money has no say in that judgment. The fee is the same whatever medication is indicated and whatever the dose; there is no molecule upcharge and no dose upcharge. Medication is unbundled. When it is prescribed, it goes to the pharmacy the patient chooses, at that pharmacy's own price, and GoodLife Health sets nothing, sees nothing and takes nothing on it. A company that earns more on one product has a reason to steer patients toward it. This one has no such reason.
Nobody at GoodLife Health earns more if Dana injects, and nobody earns less if she never does.
There is one honest complication, and it is better to hear it now than in month one. The model runs on labs, and labs are blood draws. The membership includes four cardiometabolic lab panels a year, drawn every 90 days. An objection to injecting medication is a different thing from an objection to any needle at all. If even a quarterly blood draw is out of the question for Dana, this membership will not suit her, because the labs are what everything else depends on. Only she can tell you which objection she means, and it is worth asking her before you raise anything else.
Dana's first three months, step by step
Before anything is charged
Dana starts with the eligibility check, a short set of questions that comes before any payment. If she passes, she moves to the intake, where she gives her history in her own words. This is the place to write down that she does not want to inject anything. The clinician should have that information from the start, alongside everything else she shares.
A preference about how a medication is taken is part of the clinical picture, and it belongs in the intake. The clinician weighs it together with the labs and history when deciding what, if anything, is indicated.
Then comes checkout. The membership is $299 a month, month to month, and $598 is charged at sign-up to cover the first two months. After checkout, a clinician reviews her intake and decides whether to accept her into care, and not everyone is accepted. If the clinician cannot accept Dana, the $598 is refunded in full. Once she is accepted, the first two months are non-refundable. Any medication billed by a pharmacy later follows that pharmacy's own return and refund policy.
Month one: the first panel
Dana's first panel is drawn before any treatment decision is made. It is called a Biomarker Audit, and it covers more than the few numbers on a typical annual workup, because each marker answers a different question.
ApoB and lipoprotein(a) speak to cardiovascular risk, and ApoB is worth tracking on its own because it can stay dangerous after the scale improves. hs-CRP covers the inflammation side of the system. HbA1c and the insulin markers show how her body is handling blood sugar. Fasting insulin can rise years before glucose moves, which is why it is measured directly instead of waiting for a glucose result to cross a line. The lipid panel fills in the rest of the cardiovascular picture. The full hormone and thyroid panels look for causes a weight-only program never checks: a thyroid quietly stalling progress, or a hormonal transition behind the change.
The results are read against optimal ranges instead of population reference ranges, and every result is in Dana's hands. You and she can look at the same numbers the clinician is reading.
Month two: reading the results together
Once the results are in, Dana has a video visit with her clinician. In her composite story, the panel shows elevated HbA1c and insulin markers, an elevated ApoB, and a thyroid within range. The thyroid result matters as much as the others, because it rules out one explanation and keeps the plan from chasing a cause that is not there.
The clinician judges that a GLP-1 medication is indicated. Knowing from the intake that Dana does not want to inject, the clinician prescribes the Wegovy pill to the pharmacy she chooses. NovoCare's published self-pay price for the pill, as of September 2026, is from $149 a month at lower doses. For context, NovoCare publishes Wegovy pens at $199 a month for the first two fills (an introductory offer for new patients through December 2026) and $349 a month after. LillyDirect lists Zepbound vials at $299 to $449 a month depending on dose. Both sets of figures are as published in September 2026. Whatever is prescribed, the pharmacy bills it directly, and the $299 membership stays $299.
That is one version of month two, and the story could have gone differently. Had the labs pointed to a thyroid problem, the plan would have started with thyroid medication where indicated. Had they pointed to a hormonal transition, hormone therapy would have been part of the conversation. Had the clinician thought an injectable the better clinical fit, Dana would have heard the reasoning, and the decision about what to fill would still have been hers. Had the labs not supported medication at all, the plan would have been built without it. Whichever way it goes, the membership includes asynchronous messaging and video visits.
Month three: the second look
In month three, Dana settles into the medication and uses messaging for the questions that come up between visits, the kind that do not justify an appointment but should not wait for one. Around the 90-day mark, her second panel is drawn, and this is where the quarterly cadence earns its place. The first panel was a starting point; the second shows whether the plan is moving the markers it was meant to move, and the clinician adjusts from there. The definitive guide describes the quarterly re-audit as what turns a prescription from a guess into a feedback loop, which is why the labs are not optional.
After the first two months, the membership continues month to month at $299.
The first three months, at a glance
| Stage | What happens | Why it matters |
|---|---|---|
| Before checkout | Eligibility check and intake | The preference about injections is on record from the start |
| Checkout and review | $598 covers the first two months; a clinician decides on acceptance | Full refund if not accepted; non-refundable once accepted; pharmacy medication follows the pharmacy's own policy |
| Month one | First Biomarker Audit | Diagnosis comes before any treatment decision |
| Month two | Video visit and plan; a prescription only if indicated | The plan follows the labs and the patient's preferences |
| Month three | Messaging and a second panel at about 90 days | Shows whether the plan is working |
What it costs, and what it does not do
The membership comes to $3,588 a year. For that, Dana has clinicians licensed in all fifty states, four cardiometabolic lab panels, every result in her hands, asynchronous messaging with the care team, and video visits. The fee is generally eligible for HSA or FSA pre-tax dollars. Medication is a separate cost, billed by the pharmacy she chooses; the cost comparison guide, using published August 2026 prices, puts the all-in monthly figure from $448 on an oral entry dose.
It matters just as much to say what the membership does not do. It does not promise a particular medication, or a particular form of one. It does not promise that insurance will cover a prescription; that is between Dana, her plan and her pharmacy. Prior authorization is the pharmacy's process, and GoodLife Health does not run it, speed it up or win it. The membership does not replace health insurance: it pairs with insurance for catastrophic coverage and replaces the primary-care relationship. And it does not promise any amount of weight loss, a remission or a cure. What it offers is a clinician who reads the whole picture every 90 days and adjusts the plan to what the labs show.
Raising it with Dana, honestly
If you do bring this up again, it may help to start where the membership starts. The first step is a blood draw and a conversation with a clinician about a result she already knows is elevated. Nobody can tell you in advance whether medication will be indicated, or in what form, because that decision waits for her labs. What you can tell her is that her preference goes into the intake in her own words. She will see every result the clinician sees, and the price does not change with what is prescribed.
Be straight about the commitment, too. Signing up means $598 at checkout for the first two months. It is refunded in full if the clinician cannot accept her and is non-refundable once she is accepted, and any pharmacy medication follows that pharmacy's own refund policy. After that it is month to month at $299. That is a real commitment of money, and she should weigh it with the facts in front of her.
The last point is the simplest. This is Dana's care, so the eligibility check and the intake are hers to complete when she is ready. Your part is making sure the conversation that leads there is an honest one.
Who this is not for
Some readers will recognize Dana's situation and still be better served elsewhere. If she needs a guarantee that she will be prescribed a pill before she signs anything, we cannot give one; that decision belongs to a clinician who has read her labs. If any blood draw at all is a deal-breaker, the quarterly panels make this the wrong fit. If the goal is the fastest, cheapest route to a GLP-1 prescription, the $99-a-month compounded app sits at one end of the market and the $20,000-a-year concierge practice at the other. GoodLife Health sits between them, prescribes branded, FDA-approved medication only, never compounded GLP-1, and will always put the labs before the medication. Someone who wants a prescription without the diagnostic work will find this slower and more expensive than they want. And if the hope is that a membership will stand in for health insurance or promise a number on the scale, this one will do neither.
Related Reading
- The True Monthly Cost of GLP-1 Telehealth: An Honest Comparison
- Cardiometabolic Optimization: The Definitive Guide
References
- NovoCare Pharmacy — Wegovy self-pay pricing (Novo Nordisk). 2026. www.novocare.com/pharmacy/wegovy.html
- Zepbound Self Pay Journey Program — LillyDirect vial pricing (Eli Lilly). 2026. zepbound.lilly.com/savings